Pushing forward in its cancer immunotherapy research, Regeneron Pharmaceuticals has struck a deal with Bluebird Bio to develop new cancer cell therapies using Regeneron’s VelociSuite® platform technologies and Bluebird Bio’s gene therapy knowledge. Under the agreement, Regeneron will invest US$100 M in Bluebird’s stock. In the five-year deal, the companies have jointly selected six initial targets and will split the research and development costs equally until an IND application has been submitted.